CRL2LRR-1 Targets a CDK Inhibitor for Cell Cycle Control in C. elegans and Actin-Based Motility Regulation in Human Cells

Developmental Cell

Volumn 19, Issue 5, 2010, Pages 753-764

  Starostina, Natalia G ^a   Simpliciano, Jennifer M ^a   McGuirk, Michael A ^a   Kipreos, Edward T ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COFILIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CAENORHABDITIS ELEGANS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; DEPOLYMERIZATION; HUMAN; HUMAN CELL; NEMATODE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ACTINS; ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL CYCLE; CELL MOVEMENT; CELL NUCLEUS; CULLIN PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETON; GERM CELLS; HUMANS; PROTEIN KINASE INHIBITORS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS;

CAENORHABDITIS ELEGANS;

EID: 78149486374     PISSN: 15345807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.devcel.2010.10.013     Document Type: Article

References (61)

1. Abbas T., Sivaprasad U., Terai K., Amador V., Pagano M., Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev. 2008, 22:2496-2506.
2. Abukhdeir A.M., Park B.H. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev. Mol. Med. 2008, 10:e19.
3. Arthur W.T., Burridge K. RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol. Biol. Cell 2001, 12:2711-2720.
4. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18:1223-1234.
5. Bernstein B.W., Bamburg J.R. ADF/Cofilin: a functional node in cell biology. Trends Cell Biol. 2010, 20:187-195.
6. Besson A., Assoian R.K., Roberts J.M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?. Nat. Rev. Cancer 2004, 4:948-955.
7. Besson A., Gurian-West M., Schmidt A., Hall A., Roberts J.M. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004, 18:862-876.
8. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
9. Blagosklonny M.V. Are p27 and p21 cytoplasmic oncoproteins?. Cell Cycle 2002, 1:391-393.
10. Bornstein G., Bloom J., Sitry-Shevah D., Nakayama K., Pagano M., Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 2003, 278:25752-25757.
11. Bosu D.R., Kipreos E.T. Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div. 2008, 3:7.
12. Child E.S., Mann D.J. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 2006, 5:1313-1319.
13. Feng H., Zhong W., Punkosdy G., Gu S., Zhou L., Seabolt E.K., Kipreos E.T. CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in Caenorhabditis elegans. Nat. Cell Biol. 1999, 1:486-492.
14. Fournier A.E., Takizawa B.T., Strittmatter S.M. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 2003, 23:1416-1423.
15. Goeze A., Schluns K., Wolf G., Thasler Z., Petersen S., Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J. Pathol. 2002, 196:8-16.
16. Grotegut S., von Schweinitz D., Christofori G., Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 2006, 25:3534-3545.
17. Gu Y., Turck C.W., Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993, 366:707-710.
18. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
19. Hedgecock E.M., Culotti J.G., Hall D.H., Stern B.D. Genetics of cell and axon migrations in Caenorhabditis elegans. Development 1987, 100:365-382.
20. Heliez C., Baricault L., Barboule N., Valette A. Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 2003, 22:3260-3268.
21. Hong Y., Roy R., Ambros V. Developmental regulation of a cyclin-dependent kinase inhibitor controls postembryonic cell cycle progression in Caenorhabditis elegans. Development 1998, 125:3585-3597.
22. Jaffe A.B., Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 2005, 21:247-269.
23. Jang L.K., Lee Z.H., Kim H.H., Hill J.M., Kim J.D., Kwon B.S. A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction. Mol. Cells 2001, 12:304-312.
24. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., Conaway J.W., Nakayama K.I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004, 18:3055-3065.
25. Kedrin D., Wyckoff J., Sahai E., Condeelis J., Segall J.E. Imaging tumor cell movement in vivo. Curr. Protoc. Cell Biol. 2007, 19. Unit 19.17.
26. Kim Y., Starostina N.G., Kipreos E.T. The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev. 2008, 22:2507-2519.
27. Knosel T., Schluns K., Stein U., Schwabe H., Schlag P.M., Dietel M., Petersen I. Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 2004, 6:23-28.
28. Lee S., Helfman D.M. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J. Biol. Chem. 2004, 279:1885-1891.
29. Liu X., Sun Y., Ehrlich M., Lu T., Kloog Y., Weinberg R.A., Lodish H.F., Henis Y.I. Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 2000, 19:5926-5935.
30. Manapov F., Muller P., Rychly J. Translocation of p21(Cip1/WAF1) from the nucleus to the cytoplasm correlates with pancreatic myofibroblast to fibroblast cell conversion. Gut 2005, 54:814-822.
31. McAllister S.S., Becker-Hapak M., Pintucci G., Pagano M., Dowdy S.F. Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol. Cell. Biol. 2003, 23:216-228.
32. McBride S.R., Leonard N., Reynolds N.J. Loss of p21(WAF1) compartmentalisation in sebaceous carcinoma compared with sebaceous hyperplasia and sebaceous adenoma. J. Clin. Pathol. 2002, 55:763-766.
33. Narumiya S., Tanji M., Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009, 28:65-76.
34. Nishitani H., Shiomi Y., Iida H., Michishita M., Takami T., Tsurimoto T. CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J. Biol. Chem. 2008, 283:29045-29052.
35. Nishiwaki K. Mutations affecting symmetrical migration of distal tip cells in Caenorhabditis elegans. Genetics 1999, 152:985-997.
36. Nobes C.D., Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 1999, 144:1235-1244.
37. Ono S. Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics. Int. Rev. Cytol. 2007, 258:1-82.
38. Pehlivan D., Gunduz E., Gunduz M., Nagatsuka H., Beder L.B., Cengiz B., Rivera R.S., Fukushima K., Palanduz S., Ozturk S., et al. Loss of heterozygosity at chromosome 14q is associated with poor prognosis in head and neck squamous cell carcinomas. J. Cancer Res. Clin. Oncol. 2008, 134:1267-1276.
39. Pellegrin S., Mellor H. Actin stress fibres. J. Cell Sci. 2007, 120:3491-3499.
40. Piano F., Schetter A.J., Morton D.G., Gunsalus K.C., Reinke V., Kim S.K., Kemphues K.J. Gene clustering based on RNAi phenotypes of ovary-enriched genes in C. elegans. Curr. Biol. 2002, 12:1959-1964.
41. Pollard T.D., Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112:453-465.
42. Richard F., Pacyna-Gengelbach M., Schluns K., Fleige B., Winzer K.J., Szymas J., Dietel M., Petersen I., Schwendel A. Patterns of chromosomal imbalances in invasive breast cancer. Int. J. Cancer 2000, 89:305-310.
43. Ridley A.J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006, 16:522-529.
44. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
45. Rodriguez-Vilarrupla A., Jaumot M., Abella N., Canela N., Brun S., Diaz C., Estanyol J.M., Bachs O., Agell N. Binding of calmodulin to the carboxy-terminal region of p21 induces nuclear accumulation via inhibition of protein kinase C-mediated phosphorylation of Ser153. Mol. Cell. Biol. 2005, 25:7364-7374.
46. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
47. Sarcinella E., Zuzarte P.C., Lau P.N., Draker R., Cheung P. Monoubiquitylation of H2A.Z distinguishes its association with euchromatin or facultative heterochromatin. Mol. Cell. Biol. 2007, 27:6457-6468.
48. Schmandke A., Strittmatter S.M. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 2007, 13:454-469.
49. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
50. Shimokawa H., Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol. Sci. 2007, 28:296-302.
51. Starostina N.G., Lim J.M., Schvarzstein M., Wells L., Spence A.M., Kipreos E.T. A CUL-2 ubiquitin ligase containing three FEM proteins degrades TRA-1 to regulate C. elegans sex determination. Dev. Cell 2007, 13:127-139.
52. Tanaka H., Yamashita T., Asada M., Mizutani S., Yoshikawa H., Tohyama M. Cytoplasmic p21(Cip1/WAF1) regulates neurite remodeling by inhibiting Rho-kinase activity. J. Cell Biol. 2002, 158:321-329.
53. Tanaka H., Yamashita T., Yachi K., Fujiwara T., Yoshikawa H., Tohyama M. Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 2004, 127:155-164.
54. Timmons L., Court D.L., Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene 2001, 263:103-112.
55. Vasudevan S., Starostina N.G., Kipreos E.T. The Caenorhabditis elegans cell-cycle regulator ZYG-11 defines a conserved family of CUL-2 complex components. EMBO Rep. 2007, 8:279-286.
56. Wang W., Eddy R., Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat. Rev. Cancer 2007, 7:429-440.
57. Winters Z.E., Hunt N.C., Bradburn M.J., Royds J.A., Turley H., Harris A.L., Norbury C.J. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur. J. Cancer 2001, 37:2405-2412.
58. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Brocker E.B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
59. Xia W., Chen J.S., Zhou X., Sun P.R., Lee D.F., Liao Y., Zhou B.P., Hung M.C. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 2004, 10:3815-3824.
60. Yokoo T., Toyoshima H., Miura M., Wang Y., Iida K.T., Suzuki H., Sone H., Shimano H., Gotoda T., Nishimori S., et al. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J. Biol. Chem. 2003, 278:52919-52923.
61. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001, 3:245-252.